IMAGE 1 - Featured Image
Placement: Featured image at the top of the article.
ARTICLE CONTENTCJC-1295 is a synthetic peptide derived from the first 29 amino acids of human growth-hormone-releasing hormone, or GHRH. It was designed to study longer-lasting activation of the GHRH receptor and downstream growth hormone and IGF-1 signaling. Naming is inconsistent.
Published human studies primarily concern a long-acting molecule equipped with a Drug Affinity Complex, or DAC, that can bind circulating albumin. Materials sold as “CJC-1295 without DAC” are chemically different and often associated with modified GRF(1-29). Results from the DAC form cannot automatically describe a non-DAC product. This guide summarizes the evidence without providing instructions for personal use.
What exactly is the CJC-1295 peptide?
The original research molecule is a tetrasubstituted analogue of human GHRH(1-29). Four amino-acid substitutions were introduced to improve resistance to rapid enzymatic breakdown. Researchers then added a maleimidopropionamide group through a lysine residue at the carboxyl terminus. That reactive component is the DAC feature. A foundational preclinical paper described the resulting albumin bioconjugate and identified CJC-1295 as a long-lasting GHRH analogue.
Naming becomes confusing because CJC-1295, CJC-1295 DAC, DAC-GRF, modified GRF(1-29), acetate salts, and TFA salts may be used inconsistently. The United States Food and Drug Administration reviewed several related bulk substances and emphasized that distinct structures and salt forms had been grouped under overlapping names. Readers new to peptide terminology can first review What Are Peptides? A Simple Introduction.
How does normal GHRH signaling work?
Natural GHRH is released by the hypothalamus and binds receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular signaling that supports growth hormone synthesis and release. Growth hormone then acts directly on tissues and stimulates production of IGF-1, especially in the liver. This axis is regulated by feedback signals, sleep, nutrition, age, sex, stress, somatostatin, and other physiological factors.
Growth hormone secretion is normally pulsatile rather than constant. A laboratory measurement taken at one moment may therefore differ markedly from another, while IGF-1 often changes more slowly. Researchers studying a GHRH analogue must specify sampling times, baseline values, assay performance, food conditions, sleep schedules, and participant characteristics. An observed hormone increase is a pharmacodynamic signal; by itself, it does not establish a health benefit or an acceptable risk profile.
What does the DAC modification change?
The maleimide-containing DAC group is intended to react with thiol groups on circulating proteins, particularly albumin. Albumin is abundant and remains in circulation far longer than unmodified GHRH fragments. Binding can protect the peptide from rapid clearance and create a long-lived conjugate. This changes exposure from a short experimental pulse into sustained receptor stimulation, so DAC and non-DAC materials represent fundamentally different research designs.
Longer exposure is not automatically better. It alters the duration, amplitude, and feedback environment of the GH/IGF-1 axis and may create different off-target questions. The FDA review noted that the reactive DAC chemistry could potentially interact with thiol groups on proteins other than albumin. Experimental work should therefore characterize conjugation, free material, degradation products, time-dependent activity, and the biological consequences of prolonged signaling rather than relying only on nominal peptide concentration.
What did the early human study report?
A randomized, placebo-controlled study published in 2006 evaluated single and repeated administrations of long-acting CJC-1295 in healthy adults. Investigators reported dose-related increases in circulating growth hormone and IGF-1. Growth hormone remained elevated for several days after a single administration, while IGF-1 remained elevated longer. The paper also described an estimated terminal half-life measured in days, consistent with the intended albumin-binding design.
These findings demonstrate biological activity under a specific protocol; they do not prove broad claims involving muscle gain, fat loss, sleep, recovery, anti-aging, athletic performance, or treatment of hormone deficiency. The sample was limited, follow-up was short, and biochemical endpoints are not the same as durable clinical outcomes. The substance used also needs precise chemical interpretation because later regulatory review found inconsistent public naming of CJC-1295-related forms.
What did later protein-profile research add?
A 2009 analysis examined stored serum from normal adults exposed to the long-acting GHRH analogue and investigated changes in circulating proteins after activation of the GH/IGF-1 axis. The work identified shifts in multiple serum proteins and illustrated how sustained endocrine signaling can influence a broader biological network. Such exploratory profiling may generate hypotheses about pathways, biomarkers, and system-wide responses.
Is “CJC-1295 without DAC” the same material?
No. In common research-market language, “without DAC” often means a tetrasubstituted 29-amino-acid GHRH fragment lacking the reactive albumin-binding extension. It is frequently called modified GRF(1-29). Its expected exposure is much shorter than that of the albumin-conjugating DAC molecule. The two materials may share the receptor target, yet their molecular masses, terminal chemistry, pharmacokinetics, sampling requirements, and experimental controls differ.
A label should therefore state the exact sequence, whether the terminal lysine and maleimide-containing group are present, the salt or counterion, and the calculated molecular mass. The CJC-1295 research listing must be evaluated according to its stated specification and batch records. A study of CJC-1295 DAC should not be cited as direct evidence for modified GRF(1-29), and the reverse is equally inappropriate.
IMAGE 2 - Analytical Research
Placement: After the section on DAC and non-DAC material identity.
Why combinations require separate evidence
Research discussions often pair a GHRH analogue with a growth hormone secretagogue such as ipamorelin. These agents act through different receptors and may produce interacting signals. That mechanistic rationale does not establish that a combination is effective, predictable, or safe. Results from CJC-1295 alone cannot be transferred to a mixture, and results from one ratio, schedule, species, or assay cannot define another.
The research catalog lists materials individually, while research categories provide navigational context.
What are the main evidence limitations?
The direct human evidence base is small and concentrated in early, short-duration studies of healthy adults. It does not provide strong answers about long-term outcomes, uncommon adverse events, reproductive effects, cancer-related questions, use in older or medically complex populations, or interactions with medicines and endocrine disorders. Claims about body composition and recovery are especially weak when they rely on hormone changes rather than controlled functional outcomes.
Regulatory review identified major gaps across CJC-1295-related forms, including uncertain chemical identity, incomplete nonclinical safety evidence, and inadequate clinical effectiveness data. Possible safety signals were also noted in animal and laboratory findings. These limitations show why absence of large clinical trials must not be presented as reassurance.
IMAGE 3 - Evidence Review
Placement: After the discussion of evidence limitations.
Why analytical identity is essential
Mass spectrometry can help confirm molecular mass, and tandem mass spectrometry can provide stronger sequence evidence. Chromatography may estimate purity and related substances, but a high purity number alone does not prove that the principal peak is the intended CJC-1295 form. DAC attachment, salt form, peptide content, counterions, water, residual solvents, oxidation, aggregation, and degradation are separate attributes requiring appropriate methods and reference standards.
For DAC material, analysis should address both the unconjugated starting substance and its capacity for protein conjugation. For non-DAC material, the report should confirm the absence of the reactive extension rather than relying on a shortened product name. Detection research using liquid chromatography and tandem mass spectrometry demonstrates that CJC-1295-related compounds and conjugates require specialized analytical strategies, further reinforcing the need for exact chemical documentation.
Research materials are not finished medicines
A laboratory peptide is not automatically an approved drug, sterile medicine, prescription product, or clinical-trial material. Those categories require validated manufacturing controls, release specifications, stability programs, sterility assurance where applicable, regulatory oversight, and evidence matched to an intended use. A research label does not establish suitability for injection, hormone management, athletic recovery, weight management, sleep improvement, anti-aging, or any other personal purpose.
Why batch documentation matters
A useful Certificate of Analysis identifies the complete product name, sequence, DAC status, salt form, batch or lot, test methods, specifications, measured results, laboratory attribution, and report date. Generic certificates, mismatched batch numbers, unexplained chromatograms, reused documents, or missing raw identifiers weaken confidence. The PrimePeptidesHub quality certificates page describes document organization, while the quality commitment explains the site’s approach to traceability and transparency.
Identity, purity, assay, stability, and microbiological quality answer different questions. A single chromatogram cannot establish all of them. Storage statements should be supported by stability data for the specific formulation and container. Clear records allow researchers to decide whether a batch matches a defined protocol and to investigate unexpected findings. They do not convert a research material into a medicine or authorize personal administration.
Key takeaway
CJC-1295 is best understood as a family of closely named but chemically distinct GHRH-related research materials. The original long-acting form uses DAC chemistry to create albumin conjugation and prolonged exposure. Early human research showed sustained increases in growth hormone and IGF-1, while later work explored broader protein changes. These studies confirm pharmacological activity under controlled conditions, not the many practical benefits promoted online.
Responsible interpretation begins with exact identity: sequence, terminal modification, DAC status, salt form, molecular mass, and batch documentation. It then matches every statement to the tested molecule, population, comparator, duration, and endpoint. Human outcome and long-term safety evidence remain limited, especially for non-DAC materials and combinations. Scientific uncertainty is therefore not a minor disclaimer; it is one of the most important conclusions supported by the current evidence.
SOURCES
1. Jetté L et al. Human GRF(1-29)-Albumin Bioconjugates Activate the GRF Receptor: Identification of CJC-1295. Endocrinology, 2005
2. Teichman SL et al. Prolonged GH and IGF-I Secretion by CJC-1295 in Healthy Adults. Journal of Clinical Endocrinology & Metabolism, 2006
3. Alba M et al. Once-Daily CJC-1295 Normalizes Growth in the GHRH Knockout Mouse. American Journal of Physiology-Endocrinology and Metabolism, 2006
4. Sackmann-Sala L et al. Activation of the GH/IGF-1 Axis by CJC-1295 Produces Serum Protein Profile Changes. Growth Hormone & IGF Research, 2009
5. Timms M et al. Confirming CJC-1295 in Equine Plasma by LC-MS/MS. Drug Testing and Analysis, 2019
6. FDA. Evaluation of CJC-1295-Related Bulk Drug Substances for the 503A Bulks List, 2024
DISCLAIMER
For research use only. CJC-1295 laboratory materials are not finished medicines, sterile products, approved therapies, or clinical-trial materials. Evidence involving CJC-1295 DAC cannot automatically establish the identity, safety, or effectiveness of a non-DAC material, another salt form, or a combination product. This educational content is not medical advice and does not describe diagnosis, treatment, dosing, preparation, injection, administration, or human or veterinary use.